INSUBCONTINENT EXCLUSIVE:
NEW DELHI: Drug major Cipla on Tuesday reported consolidated profit of Rs 178.61 crore for the quarter ended March 31
The firm had posted a loss of Rs 61.79 crore in the corresponding quarter last fiscal.
Total income of the company stood at Rs 3,737.9
crore, up 3.69 per cent against Rs 3,604.79 crore in the year-ago period.
The Board of Directors of the company recommended final dividend
of Rs 3 per equity share (face value of Rs 2 each) for the financial year
The dividend is subject to approval at the ensuing annual general meeting of the company.
Net sales or income from the operations saw a
marginal increase to Rs 3,495.81 crore against Rs 3,487.04 crore in the year-ago period.
Diluted EPS (earnings per share) came in at Rs 2.22
In a year ago period, the figure stood at Rs -0.77.
Segment wise, pharmaceuticals revenue rose 3.12 per cent to Rs 3,665.07 crore against Rs
3,554.06 crore in the corresponding quarter last year
Revenue from ventures came in at Rs 34.26 crore against Rs 28.32 crore YoY.
